Drug
Vitamin K antagonists
Vitamin K antagonists is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 3Large-scale testing
1(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (100.0%)
Trials by Status
terminated125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completed
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
NCT02864758
completed
Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)
NCT02240667
completed
Real-Life Evidence on Stroke Prevention in SPAF
NCT02485873
terminatedphase_3
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
NCT01164046
Clinical Trials (4)
Showing 4 of 4 trials
NCT02864758
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
NCT02240667
Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)
NCT02485873
Real-Life Evidence on Stroke Prevention in SPAF
NCT01164046Phase 3
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4